- Home
- LRMR vs NGNE Comparison
LRMR vs NGNE Comparison
Compare LRMR & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- NGNE
- Stock Information
- Founded
- LRMR N/A
- NGNE 2003
- Country
- LRMR United States
- NGNE United States
- Employees
- LRMR N/A
- NGNE N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- LRMR Health Care
- NGNE Health Care
- Exchange
- LRMR Nasdaq
- NGNE Nasdaq
- Market Cap
- LRMR 309.8M
- NGNE 325.3M
- IPO Year
- LRMR N/A
- NGNE N/A
- Fundamental
- Price
- LRMR $3.89
- NGNE $19.20
- Analyst Decision
- LRMR Strong Buy
- NGNE Strong Buy
- Analyst Count
- LRMR 8
- NGNE 7
- Target Price
- LRMR $17.88
- NGNE $41.86
- AVG Volume (30 Days)
- LRMR 1.4M
- NGNE 113.3K
- Earning Date
- LRMR 10-29-2025
- NGNE 08-11-2025
- Dividend Yield
- LRMR N/A
- NGNE N/A
- EPS Growth
- LRMR N/A
- NGNE N/A
- EPS
- LRMR N/A
- NGNE N/A
- Revenue
- LRMR N/A
- NGNE N/A
- Revenue This Year
- LRMR N/A
- NGNE N/A
- Revenue Next Year
- LRMR N/A
- NGNE N/A
- P/E Ratio
- LRMR N/A
- NGNE N/A
- Revenue Growth
- LRMR N/A
- NGNE N/A
- 52 Week Low
- LRMR $1.61
- NGNE $6.88
- 52 Week High
- LRMR $9.50
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- LRMR 54.32
- NGNE 44.10
- Support Level
- LRMR $3.59
- NGNE $18.00
- Resistance Level
- LRMR $4.08
- NGNE $20.67
- Average True Range (ATR)
- LRMR 0.28
- NGNE 1.02
- MACD
- LRMR -0.01
- NGNE -0.01
- Stochastic Oscillator
- LRMR 58.33
- NGNE 42.64
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.